
1. antivir ther. 2006;11(7):947-52.

short-term lamivudine therapy hbeag-negative chronic active hepatitis b in
taiwan.

chien rn(1), liaw yf.

author information: 
(1)liver research unit, chang gung memorial hospital, chang gung university,
keelung, taiwan. ronald@adm.cgmh.org.tw

lamivudine treatment hepatitis b e antigen (hbeag)-negative hepatitis b
virus (hbv) dna-positive chronic hepatitis b (chb) patients associated with
poor sustained response. previous study shown short-term lamivudine
therapy hbeag-positive patients alanine aminotransferase (alt) > 5x upper
limit normal (uln) could achieve high hbeag response rate low lamivudine
resistance rate. we, therefore, prospectively treated 85 hbeag-negative chb
patients alt > 5x uln lamivudine 6-12 months. mean pretreatment
levels follows: alt (normal < 36 u/i) 533 u/i (range: 180-2,418 u/i);
total bilirubin (normal < 1.3 mg/dl) 2.0 mg/dl (range: 0.2-29.6 mg/dl), hbv dna
(normal, undetectable) 1.6 x 10(8) copies/ml (range: 1.4 x 10(5)-1.7 x 10(9)
copies/ml). mean 7.4 months (6-12 months) treatment, 69 (81%) patients
achieved complete response. follow-up, 12 months stopping lamivudine
therapy, 33 (39%) patients showed sustained complete response. patients with
sustained response younger relapsed patients (39.7 +/- 11.9 years
versus 47.0 +/- 10.3 years; p = 0.005). emergence lamivudine-resistant
variant hbv documented two patients (2%). concluded in
hbeag-negative chronic hepatitis b patients alt levels 5x uln, 6-12 
month course lamivudine therapy may achieve sustained off-treatment
response approximately one-third patients.


pmid: 17302259  [indexed medline]

